What is the TAK-113-4002 Study?
This is a Phase 4 study to learn more about an approved cancer drug. Researchers are studying how the drug affects blood pressure in Black/African American and Latino/Hispanic adults with metastatic colorectal cancer (mCRC). mCRC is Stage 4 cancer.
Support may be available to help make participation easier, such as compensation for your time and reimbursement for travel.
Why is this research study being done?
High blood pressure is a common side effect with this cancer drug. The data collected up to this point suggest that Black/African American and Latino/Hispanic adults are not at greater risk for an increase in blood pressure.
This study may help doctors better understand the risk of high blood pressure in Black/African American and Latino/Hispanic adults with mCRC who are treated with this drug.
Who can participate?
Adults with Stage 4 colorectal cancer are invited to see if they may qualify for the study.
Age
Adults 18 years of age or older
Treatment
Have tried at least 2 cancer treatments before
Ethnicity
Black/African American or Latino/Hispanic
Diagnosis
Stage 4 (metastatic) colorectal cancer
Other
There are other requirements. The study doctor will check to see if you qualify for the study.
Treatment is given in 4-week cycles. The cancer drug is taken daily by mouth for 3 weeks, followed by a 1-week break.
For the first 3 cycles, participants will visit the study clinic on Day 1 and Day 21 of each cycle. For Cycle 4 and beyond, participants will visit the study clinic on Day 1.
What health checks and tests can I expect?
At study visits, participants may have health checks and tests to monitor their cancer and check for side effects.
Physical
exam
Vital
signs
Blood
tests
Urine
test
Pregnancy test
(if applicable)
ECG heart
test
Echo or MUGA
heart test
Tumor scans
(at 8-week
intervals)
ECG = electrocardiogram
Echo = echocardiogram
MUGA = multigated acquisition
Find a study clinic location near you
To find a study clinic location near you, enter your ZIP code below.